Efinopegdutide Dosing Guide: Schedule, Titration & What to Expect Each Week

Introduction

Efinopegdutide is dosed once weekly by subcutaneous injection. The phase 2a MASH trial used a target dose of 10 mg weekly with a titration period to reduce GI side effects. Because the drug isn’t FDA-approved, there’s no official prescribing information yet, and dosing details come from published trial protocols.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is the Standard Efinopegdutide Dosing Schedule?

The Romero-Gomez 2023 Journal of Hepatology phase 2a MASH trial titrated efinopegdutide from a starting dose up to 10 mg weekly over approximately 4 weeks. Patients started at lower doses and stepped up weekly or biweekly until reaching the maintenance 10 mg dose.

Quick Answer: Efinopegdutide is given once weekly subcutaneously

This is similar in structure to other weekly GLP-1 drug titrations. The slow ramp lets the gut and brain adapt to receptor activation, reducing peak nausea and vomiting compared to starting at the full dose.

Phase 3 dosing will be finalized based on phase 2b results. Higher doses may be tested for obesity. The 10 mg dose appears optimal for MASH based on liver-fat dose-response data so far.

Why Does Efinopegdutide Need Titration?

GLP-1 receptor activation causes nausea and slowed gastric emptying. Starting at maximum dose would cause severe symptoms in many patients. A 4-week titration usually reduces severe nausea rates by 2 to 3x compared to no titration.

Glucagon receptor activation can also produce side effects (modest heart rate increases, possible lipid changes), though efinopegdutide’s reportedly GLP-1-weighted ratio means these signals are smaller than for pemvidutide.

What Does Week 1 Feel Like?

At the lowest starting dose, most patients in the phase 2a trial reported mild nausea within 24 to 48 hours of first injection. The nausea typically peaks within the first 2 to 3 days then improves. Appetite suppression begins within the first week, with patients noticing they feel full faster and have less interest in food.

Some patients experience minimal first-week symptoms, especially those who naturally tolerate GLP-1 effects well. Early weight changes are mostly water and gut content shifts, not fat loss.

What Changes During Weeks 2 Through 4?

The titration moves through intermediate doses during weeks 2 to 4. Each dose step may produce a brief flare of GI symptoms that fades within days. By week 4, most patients are at or near the 10 mg target dose.

Mean weight loss by week 4 in the phase 2a trial was around 2 to 3% from baseline. Liver fat starts to drop visibly on imaging by this point in MASH patients.

What Happens at the 10 Mg Maintenance Dose?

The 10 mg weekly dose is the highest tested in published phase 2 data and produced 8.5% mean weight loss at 24 weeks in MASH patients. Liver fat fell 72.7% over the same period.

Side effects at maintenance dose are usually mild and intermittent. Steady-state plasma levels are reached after about 4 to 5 weekly doses, after which efficacy and side effect patterns stabilize.

For non-MASH obesity, optimal dose is still being defined. Larger doses may be tested in phase 3 obesity trials.

How Does Efinopegdutide Dosing Compare to Semaglutide?

Semaglutide for obesity (Wegovy®) titrates from 0.25 mg to 2.4 mg over 16 weeks. Efinopegdutide titrates to 10 mg over about 4 weeks. The mg numbers aren’t comparable because the molecules have different potencies and receptor profiles.

Efinopegdutide’s faster titration may reflect the drug’s tolerability profile or trial design choices. Phase 3 dosing may extend titration if larger populations show more intolerance.

How Does Efinopegdutide Dosing Compare to Tirzepatide?

Tirzepatide for obesity titrates from 2.5 mg to 15 mg over 20 weeks. Efinopegdutide’s 4-week titration to 10 mg is much faster.

Again, the mg numbers aren’t directly comparable. Tirzepatide and efinopegdutide are different molecules with different receptor profiles.

What If I Miss a Dose?

A missed efinopegdutide dose can usually be taken within 1 to 2 days of the scheduled time without significant problems. Beyond that, the standard guidance is to skip that dose and resume the next regular weekly injection.

Two missed doses in a row may require re-titration starting from a lower dose because the gut may have lost some adaptation. Three or more missed doses definitely warrants a clinician check-in.

The 7 to 10 day half-life means that even with one missed dose, residual drug concentrations stay above therapeutic threshold for the appetite-suppression effects, though the liver-fat effect may diminish.

Can the Dose Be Adjusted Down?

Yes, if side effects don’t improve at the 10 mg dose, dropping back to a lower dose is reasonable. Some patients may maintain on intermediate doses long-term if those provide adequate effect with better tolerability.

Re-escalation to 10 mg can happen later if symptoms settle.

What Injection Technique Is Used?

Subcutaneous injection into the abdomen, thigh, or upper arm. Standard GLP-1 injection technique applies: rotate sites week to week, clean the injection site, use a fresh needle for each dose, and inject at a 90-degree angle.

Bring the drug to room temperature for 15 to 30 minutes before injecting to reduce stinging. Don’t inject cold.

How Is Efinopegdutide Supplied?

In clinical trials, efinopegdutide is supplied as a solution in vials or prefilled syringes. The commercial pen device (when approved) will likely be a multi-dose pen similar to Wegovy or Zepbound®, with dialable dose options.

What About Timing of Day?

Any time of day works because of the long half-life. Most patients pick the same day each week for consistency. Some prefer evening injection so peak nausea hits during sleep; others prefer morning. There’s no clinical benefit to one over the other.

How Long Does It Take to Feel Effects?

Appetite suppression usually begins within the first week. Weight loss typically reaches 2 to 3% by week 4, 5 to 6% by week 8, and continues through month 6. Liver fat reduction is detectable on MRI by week 8 to 12.

Maximum weight loss in phase 2a trial was at the 24-week endpoint (the trial duration). Whether efinopegdutide continues weight loss beyond 24 weeks isn’t yet known from published data.

What If Side Effects Don’t Improve?

If GI side effects persist past 6 to 8 weeks at the 10 mg dose, options include extending time at the current dose, dropping to a lower dose, or stopping. Severe persistent symptoms (vomiting that prevents fluid intake, severe abdominal pain) warrant clinician evaluation.

About 8 to 10% of phase 2 patients discontinued for AEs at 10 mg, similar to other GLP-1 drugs. The other 90% tolerated the full dose.

What Happens If I Stop Efinopegdutide?

Weight regain after stopping GLP-1 drugs is common. The STEP 1 extension showed about two-thirds of semaglutide weight loss returns within a year of stopping. Efinopegdutide is likely similar.

Liver fat may also begin to reaccumulate after stopping. The 24-week MASH trial showed substantial liver fat reductions, but maintaining those reductions probably requires continued therapy.

What About Access in 2026?

Efinopegdutide isn’t commercially available. The only legitimate access path is through clinical trials. Compounded efinopegdutide is not legally available because the drug isn’t FDA-approved.

Patients seeking GLP-1 therapy now have practical options through TrimRx with compounded semaglutide or tirzepatide. The free assessment quiz matches patients to the right approved option.

How Does Efinopegdutide’s Half-life Affect Dose Timing Flexibility?

The 7 to 10 day half-life gives some flexibility in dose timing. Patients who normally inject on Sunday but find themselves traveling and unable to inject until Tuesday can usually shift without significant problems, especially after reaching steady state at week 4 to 5.

Larger shifts (3 to 4 days late) reduce plasma levels but usually don’t cause complete loss of effect. Skipping an entire week drops levels meaningfully but still leaves residual drug above receptor activation threshold.

That said, consistency matters. Patients who maintain regular weekly dosing have more predictable side effect patterns and steadier weight loss curves than patients who shift timing repeatedly.

What Does the Typical First Month Look Like?

Week 1: First injection at starting dose. Mild nausea typically within 1 to 2 days. Appetite suppression begins. Some mild fatigue or brain fog possible. Weight loss minimal (mostly water).

Week 2: Possible second titration step depending on protocol. Side effects may peak briefly. Appetite suppression strengthens. Weight loss begins to show on the scale.

Week 3: Third titration step. Body continues adapting. Side effects easing for most patients.

Week 4: Reach 10 mg maintenance dose. Cumulative weight loss 2 to 3%. Side effects substantially eased for most patients.

How Should Patients Prepare for the First Injection?

Before the first injection, patients should have a clinician walk-through of injection technique. Many trial protocols include a hands-on training session at the first dose visit.

Practical preparation:

Choose an injection site (abdomen, thigh, upper arm). Clean the site with an alcohol swab. Bring the drug to room temperature 15 to 30 minutes before injecting. Have ginger chews or other mild nausea aids on hand for the first few days. Plan light meals (not heavy fatty foods) for the day of injection.

Hydration matters. Aim for 64 to 80 oz of water daily starting a few days before the first injection to establish a baseline.

What If a Patient Gains Weight in the First Week?

Some patients see no weight change or even a small gain in the first week. This is usually water retention from changed eating patterns, hormonal shifts, or normal day-to-day fluctuation. It’s not a sign that the drug isn’t working.

Sustained weight loss usually shows up by week 3 to 4. Patients who haven’t lost any weight by week 8 may need dose adjustment or evaluation for other contributing factors.

How Does Efinopegdutide Titration Affect Daily Life?

The first 4 to 8 weeks can be disruptive. Patients should plan for reduced energy, possible GI symptoms, and shifts in eating patterns. Major life events (travel, demanding work projects, holidays with rich foods) are easier to manage if scheduled outside the early titration period.

After reaching maintenance dose and adapting, most patients describe daily life as normal with the added benefit of reduced food preoccupation.

What If a Patient Feels Nothing on Efinopegdutide?

A small minority of patients respond minimally to GLP-1 drugs. If 8 to 12 weeks at maintenance dose produces no weight loss and minimal appetite change, the patient is probably a low responder.

Options include extending time at the current dose, increasing dose (if higher doses are available), switching to a different GLP-1 drug with different receptor coverage, or stopping and considering non-GLP-1 approaches.

Bottom line: No FDA-approved dose schedule yet

FAQ

Can I Start Efinopegdutide at the Full 10 Mg Dose?

No. Trials titrate to limit GI side effects. Starting at full dose would cause severe nausea and vomiting in many patients.

How Long Until I See Weight Loss?

Most patients see 2 to 3% loss by week 4, 5 to 6% by week 8, and 8 to 9% by week 24 based on phase 2 data.

What Time of Day Should I Inject?

Any time works. Pick a consistent day and time for routine.

Does Efinopegdutide Treat Type 2 Diabetes?

It produces modest HbA1c reductions but isn’t being developed as a primary diabetes therapy.

Can I Take Other GLP-1 Drugs with Efinopegdutide?

No. Don’t combine GLP-1 agonists.

What If I’m on Insulin?

Insulin doses typically need reduction when starting any GLP-1 drug to avoid hypoglycemia. Coordinate with your clinician.

Will I Need to Inject Forever?

Probably, for ongoing weight and liver fat benefit. The biology of regain after stopping applies across the GLP-1 class.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.